½ÃÀ庸°í¼­
»óǰÄÚµå
1620334

¼¼°èÀÇ Ç÷¾× ÀÀ°í ºÐ¼®±â ½ÃÀå ±Ô¸ð : Áö¿ªº°, ¹üÀ§ ¹× ¿¹Ãø

Global Blood Coagulation Analyzer Market Size By Technology (Optical Technology, Electrochemical Technology), By Test Type (APTT, Fibrinogen, PT), By Distribution Channels (Clinical Laboratory, Point-of-Care (POC)), By Geographic Scope And Forecast

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Verified Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 202 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Ç÷¾× ÀÀ°í ºÐ¼®±â ½ÃÀå ±Ô¸ð ¹× Àü¸Á

Ç÷¾× ÀÀ°í ºÐ¼®±â ½ÃÀå ±Ô¸ð´Â 2024³â 40¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, 2024-2031³â°£ 5.90%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2031³â¿¡´Â 64¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ç÷¾× ÀÀ°í ºÐ¼®±â´Â Ç÷¾×ÀÇ ÀÀ°í ´É·ÂÀ» Æò°¡Çϴ Ư¼ö ÀÇ·á±â±â·Î, ºÎÁ¤ ÃâÇ÷ ¹× ÀÀ°í¸¦ µ¿¹ÝÇÑ Áúº´À» ½Äº°Çϰí Ä¡·áÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ´Ù¸¥ Ȱµ¿À¸·Î´Â ÇÁ·ÎÆ®·Òºó ½Ã°£(PT), Ȱ¼ºÈ­µÈ ºÎºÐ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ½Ã°£(aPTT), ÇǺ긮³ë°Õ ¼öÄ¡ µî ´Ù¾çÇÑ ÀÀ°í ¸Å°³º¯¼ö¸¦ Æò°¡ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °á°ú´Â ÀÇ·áÁøÀÌ Ç×ÀÀ°íÁ¦ º¹¿ë ÁßÀΠȯÀÚ¸¦ ¸ð´ÏÅ͸µÇϰí, Ç÷¿ìº´°ú °°Àº ÀÀ°í¼º ÁúȯÀ» Áø´ÜÇϰí, ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ ¹× Æó»öÀüÁõ°ú °°Àº ÁúȯÀ» °ü¸®ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº Á¤È®ÇÏ°í ½Ã±âÀûÀýÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÔÀ¸·Î½á È¿°úÀûÀÌ°í ¾ÈÀüÇÑ È¯ÀÚ Ä¡·á¸¦ º¸ÀåÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

Ç÷¾× ÀÀ°í ºÐ¼®±â´Â ±â¼ú ¹ßÀü°ú °³ÀÎ ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ Àü¸ÁÀÌ ¹à½À´Ï´Ù. ÇöÀå °Ë»ç, ÀüÀÚ ÀÇ·á ±â·Ï°úÀÇ ÅëÇÕ, °¡Á¤¿ë ¼ÒÇüÈ­·Î ÀÎÇØ ÀÀ°í °Ë»çÀÇ ÆíÀǼº°ú Á¤È®¼ºÀÌ Çâ»óµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, º¸´Ù Á¤¹ÐÇÑ °Ë»ç¿Í ½Ç½Ã°£ ¸ð´ÏÅ͸µÀÌ °¡´ÉÇÑ º¸´Ù º¹ÀâÇÑ ºÐ¼®±â±âÀÇ °³¹ß·Î ȯÀÚ °á°ú¸¦ °³¼±Çϰí ÀÓ»ó ¾÷¹«¸¦ °£¼ÒÈ­ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÇコÄÉ¾î »ê¾÷ÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ºÐ¼® Àåºñ´Â ÀÀ°í Áúȯ Ä¡·á¿Í Á¤¹ÐÀÇ·áÀÇ ¹ßÀü¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Ç÷¾× ÀÀ°í ºÐ¼®±â ¼¼°è ½ÃÀå ¿ªÇÐ

Ç÷¾× ÀÀ°í ºÐ¼®±â ¼¼°è ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ½ÃÀå ¿ªÇÐ

ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

Ç÷¾× ÁúȯÀÇ À¯º´·ü Áõ°¡:

Ç÷¾× ÁúȯÀÇ À¯º´·ü Áõ°¡: Ç÷¾× ÀÀ°í ºÐ¼®±â´Â ȯÀÚÀÇ Ç÷¾× Áúȯ À¯º´·ü Áõ°¡·Î ÀÎÇØ ³ôÀº ¼ö¿ä¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¼¼°è Ç÷¿ìº´ ¿¬¸ÍÀÇ 2019³â ¿¬·Ê ¼¼°è Á¶»ç¿¡ µû¸£¸é Àü ¼¼°è Ç÷¿ìº´ ȯÀÚ´Â 32¸¸ 4,000¿© ¸íÀ¸·Î Àü³â ´ëºñ 7% Áõ°¡Çß½À´Ï´Ù.

³ë·ÉÀα¸ Áõ°¡ :

¼¼°è Àα¸ÀÇ °í·ÉÈ­¿¡ µû¶ó ½ÉÇ÷°ü Áúȯ°ú ÀÀ°í Àå¾ÖÀÇ À§ÇèÀÌ ³ô¾ÆÁö¸é¼­ ÀÀ°í °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À¯¿£ÀÇ 'World Population Prospects 2019' º¸°í¼­¿¡ µû¸£¸é, 2050³â¿¡´Â Àü ¼¼°è Àα¸ 6¸í Áß 1¸íÀÌ 65¼¼ ÀÌ»óÀÌ µÉ °ÍÀ̸ç, ÀÌ´Â 2019³â 11¸í Áß 1¸í¿¡¼­ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿Ü°ú ¼ö¼ú Áõ°¡ :

Àü ¼¼°è ¿Ü°ú ¼ö¼ú Áõ°¡·Î ¼ö¼ú Àü ¹× ¼ö¼ú ÈÄ °ü¸®¸¦ À§ÇÑ ÀÀ°í °Ë»ç°¡ ´õ ¸¹ÀÌ ÇÊ¿äÇϸç, 2021³â ¶õ¼ÂÁö¿¡ ¹ßÇ¥µÈ º¸°í¼­¿¡ µû¸£¸é 2008³âºÎÅÍ 2018³â±îÁö Àü ¼¼°è ¼ö¼ú °Ç¼ö´Â 38.2% Áõ°¡ÇÏ¿© ¸Å³â 3¾ï 1,300¸¸ °Ç¿¡ ´ÞÇß½À´Ï´Ù. ¿¡ À̸£·¶´Ù°í ÇÕ´Ï´Ù.

ÀÀ°í ºÐ¼®±âÀÇ ±â¼úÀû Áøº¸ :

¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)ÀÇ 2022³â º¸°í¼­¿¡ µû¸£¸é, ÀϹÝÀûÀÎ °Ë»ç½Ç ½Ã¼úÀÌ 30-60ºÐ °É¸®´Â ¹Ý¸é, ÇöÀå ÀÀ°í ºÐ¼®±â´Â ÀÌ¹Ì 1-3ºÐ Á¤µµ¸é °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù. °á°ú¸¦ ¾òÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

ÁÖ¿ä °úÁ¦

±â¼úÀÇ º¹À⼺:

Ç÷¾× ÀÀ°í ºÐ¼®±â´Â °íµµÀÇ ±â¼ú°ú Á¤¹Ð ¿£Áö´Ï¾î¸µÀÌ ÇÊ¿äÇÑ º¹ÀâÇÑ ÀåºñÀÔ´Ï´Ù. Á¤È®¼º°ú ½Å·Ú¼ºÀ» À¯ÁöÇϸ鼭 ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü¿¡ ´ëÀÀÇÏ´Â °ÍÀº ¾î·Á¿ï ¼ö ÀÖ½À´Ï´Ù. °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ Á¦Á¶¾÷ü´Â ²÷ÀÓ¾øÀÌ ½Ã½ºÅÛÀ» Çõ½ÅÇÏ°í ¾÷±×·¹À̵åÇØ¾ß Çϸç, À̸¦ À§ÇØ ¸¹Àº ¿¬±¸ °³¹ß ºñ¿ëÀÌ ÇÊ¿äÇÕ´Ï´Ù.

µ¥ÀÌÅÍ °ü¸®:

ÃֽŠÀÀ°í ºÐ¼®±â´Â ¹æ´ëÇÑ ¾çÀÇ µ¥ÀÌÅ͸¦ »ý¼ºÇϱ⠶§¹®¿¡ ÀÌ·¯ÇÑ µ¥ÀÌÅÍ´Â ½ÅÁßÇÏ°Ô ±â·Ï, ÀúÀå ¹× Ã³¸®ÇØ¾ß ÇÕ´Ï´Ù. °á°ú¸¦ ½Å·ÚÇÒ ¼ö ÀÖ°í ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï Çϱâ À§Çؼ­´Â È¿°úÀûÀÎ µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀ» ´Ù¸¥ º´¿ø Á¤º¸ ½Ã½ºÅÛ°ú ÅëÇÕÇÏ´Â °ÍÀº ¾î·Á¿ï ¼ö ÀÖ½À´Ï´Ù.

Á¦Ç° ±³Á¤ ¹× À¯Áöº¸¼ö:

ÀÀ°í ºÐ¼®±âÀÇ Á¤È®¼º°ú ½Å·Ú¼ºÀ» º¸ÀåÇϱâ À§Çؼ­´Â Á¤±âÀûÀÎ ±³Á¤ ¹× À¯Áöº¸¼ö°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áö¼ÓÀûÀÎ Çʿ伺Àº ƯÈ÷ ¸®¼Ò½º°¡ Á¦ÇÑµÈ ÀÇ·á ½Ã¼³ÀÇ °æ¿ì, Àåºñ µµÀÔÀ¸·Î ÀÎÇÑ ¿î¿µ È¿À²¼º°ú ºñ¿ë¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

³ôÀº ºñ¿ë:

Ç÷¾× ÀÀ°í ºÐ¼®±â´Â ±¸ÀÔ ¹× À¯Áö °ü¸® ºñ¿ëÀÌ ¸¹ÀÌ µì´Ï´Ù. ¿©±â¿¡´Â ±â±â º»Ã¼, ¼Ò¸ðǰ, Á¤±âÀûÀÎ ±³Á¤ ¹× À¯Áöº¸¼öÀÇ Çʿ伺 µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ³ôÀº °¡°ÝÀº ¼Ò±Ô¸ð Áø·á¼Ò³ª °Ë»ç½Ç¿¡¼­´Â °¨´çÇÒ ¼ö ¾ø´Â ¼öÁØÀ̸ç, °í±Þ ÀÀ°í Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Á¦ÇÑÇÕ´Ï´Ù.

ÁÖ¿ä µ¿Çâ

Point-of-care °Ë»ç

Ç÷¾×ÀÀ°í POC(Point-of-Care) °Ë»ç´Â °Ëü¸¦ Áß¾Ó °Ë»ç½Ç·Î º¸³»Áö ¾Ê°í ±× ÀÚ¸®¿¡¼­ ¹Ù·Î °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Ù´Â ÀåÁ¡ ¶§¹®¿¡ ÀαⰡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼ÀÇ ¹è°æ¿¡´Â º¸´Ù ºü¸¥ Áø´Ü °á°ú¿Í ȯÀÚÀÇ ÆíÀǼº Çâ»ó¿¡ ´ëÇÑ ¿ä±¸°¡ ÀÖÀ¸¸ç, POC ±â±âÀÇ ¼ÒÇüÈ­ ¹× »ç¿ë ÆíÀǼº Çâ»óÀ¸·Î ÀÀ±Þ½Ç, ¿Ü·¡ Áø·á¼Ò µî ´Ù¾çÇÑ ÀÓ»ó ÇöÀå¿¡¼­ ½Å¼ÓÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

ÀüÀÚÀǹ«±â·Ï(EHR)°úÀÇ ÅëÇÕ:

Ç÷¾× ÀÀ°í ºÐ¼®±â¿Í ÀüÀÚ ÀÇ·á ±â·Ï(EHR)ÀÇ ¿¬µ¿Àº µ¥ÀÌÅÍ °ü¸® ¼Óµµ¸¦ ³ôÀ̰í ȯÀÚ Ä¡·á¸¦ °³¼±Çϱâ À§ÇØ Á¡Á¡ ´õ ¸¹ÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ ÀÎÅÍÆäÀ̽º´Â ¿øÈ°ÇÑ µ¥ÀÌÅÍ Àü¼Û, ȯÀÚ Á¤º¸¿¡ ´ëÇÑ ½Ç½Ã°£ ¾×¼¼½º, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü °£ÀÇ Çù¾÷À» °³¼±ÇÏ¿© ÀÀ°í °Ë»ç ¹× °ü¸®ÀÇ Àü¹ÝÀûÀÎ È¿À²¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù.

¼ÒÇüÈ­ ¹× È޴뼺:

¼ÒÇü ÈÞ´ë¿ë Ç÷¾× ÀÀ°í ºÐ¼®±âÀÇ °³¹ßÀº Å« Ãß¼¼ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼ÒÇü ±â±â´Â ´ÙÀç´Ù´ÉÇÏ°í °£ÆíÇϸç, ¿ø°ÝÁö³ª ÀçÅÃÄ¡·á µî ´Ù¾çÇÑ »óȲ¿¡¼­ ÀÀ°í °Ë»ç¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÈÞ´ë¿ë ºÐ¼®±â´Â ºÐ»êÇü °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ´Â °ÍÀÔ´Ï´Ù.

°í±Þ ±â¼ú ¹× ÀÚµ¿È­:

Ç÷¾× ÀÀ°í ºÐ¼®±â´Â ÀÚµ¿È­ ¹× ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ±× À¯¿ë¼ºÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È­µÈ ½Ã·á ó¸®, µ¥ÀÌÅÍ Ã³¸®, °á°ú º¸°í¿Í °°Àº ±â´ÉÀÌ Á¡Á¡ ´õ º¸ÆíÈ­µÇ¾î Á¤È®µµ°¡ Çâ»óµÇ°í, ¼öÀÛ¾÷À¸·Î ÀÎÇÑ ½Ç¼ö°¡ »ç¶óÁö°í, °Ë»ç 󸮷®ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • ½ÃÀåÀÇ Á¤ÀÇ
  • ½ÃÀå ¼¼ºÐÈ­
  • Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå °³¿ä
  • ½ÃÀå ÇÏÀ̶óÀÌÆ®

Á¦3Àå ½ÃÀå °³¿ä

  • ½ÃÀå ±Ô¸ð¿Í ¼ºÀå °¡´É¼º
  • ½ÃÀå µ¿Çâ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • PorterÀÇ Five Forces ºÐ¼®

Á¦4Àå Ç÷¾× ÀÀ°í ºÐ¼®±â ½ÃÀå : ºÐ¼® Àåºñ À¯Çüº°

  • ÀÓ»ó °Ë»ç ºÐ¼® Àåºñ
  • POC(Point of Care) ºÐ¼® Àåºñ

Á¦5Àå Ç÷¾× ÀÀ°í ºÐ¼®±â ½ÃÀå : ¿ëµµº°

  • Á¤±â ÀÀ°í °Ë»ç
  • Ư¼ö ÀÀ°í °Ë»ç
  • Ç÷ÀüÁõ °Ë»ç
  • ±âŸ ¿ëµµ

Á¦6Àå Ç÷¾× ÀÀ°í ºÐ¼®±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Áø·á¼Ò ¹× ÀÇ»ç »ç¹«¼Ò
  • Áø´Ü¼¾ÅÍ
  • ¿¬±¸±â°ü

Á¦7Àå Áö¿ªº° ºÐ¼®

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÇÁ¶û½º
  • ÀÌÅ»¸®¾Æ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • ÀϺ»
  • Àεµ
  • È£ÁÖ
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¾Æ¸£ÇîÆ¼³ª
  • Ä¥·¹
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

Á¦8Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ

Á¦9Àå °æÀï ±¸µµ

  • ÁÖ¿ä ±â¾÷
  • ½ÃÀå Á¡À¯À² ºÐ¼®

Á¦10Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Maccura Biotechnology Co. Ltd.
  • Diagnostica Stago SAS
  • Helena Laboratories

Á¦11Àå ½ÃÀå Àü¸Á°ú ±âȸ

  • ½Å±â¼ú
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • ÅõÀÚ ±âȸ

Á¦12Àå ºÎ·Ï

  • ¾à¾î ¸®½ºÆ®
  • ÃâÀü°ú Âü°í ¹®Çå
LSH 25.01.03

Blood Coagulation Analyzer Market Size And Forecast

Blood Coagulation Analyzer Market size was valued at USD 4.07 Billion in 2024 and is projected to reach USD 6.43 Billion by 2031 , growing at a CAGR of 5.90% from 2024 to 2031. A blood coagulation analyzer is a specialized medical instrument that evaluates the blood's ability to clot, which is critical in identifying and treating disorders involving irregular bleeding or clotting. These analyzers assess a variety of coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen levels, among others. The findings assist healthcare providers in monitoring patients undergoing anticoagulant medication, diagnosing clotting diseases such as hemophilia, and managing illnesses such as deep vein thrombosis and pulmonary emboli. By providing precise and timely data, these technologies help to ensure effective and safe patient care.

The blood coagulation analyzers look positive, thanks to technological improvements and rising demand for individualized therapy. Point-of-care testing, integration with electronic health records, and home miniaturization are all predicted to improve the ease and accuracy of coagulation tests.

Furthermore, the development of more complex analyzers capable of thorough testing and real-time monitoring is likely to enhance patient outcomes and streamline clinical operations. As the healthcare industry evolves, these analyzers will be critical to the treatment of coagulation diseases and the growth of precision medicine.

Global Blood Coagulation Analyzer Market Dynamics

The key market dynamics that are shaping the global blood coagulation analyzer market include:

Key Market Drivers:

Increasing Prevalence of Blood Disorders:

Blood coagulation analyzers are in high demand due to the increasing prevalence of blood diseases among patients. According to the World Federation of Hemophilia's Annual Global Survey 2019, there were over 324,000 people with hemophilia globally, up 7% over the previous year.

Rising Geriatric Population:

As the world's population ages, there is a greater risk of cardiovascular disease and clotting disorders, increasing the demand for coagulation tests. According to the United Nations' World Population Prospects 2019 report, by 2050, one in every six persons worldwide will be over the age of 65, up from one in every eleven in 2019.

Increasing Surgical Procedures:

Increasing surgical procedures worldwide need more coagulation tests for pre- and post-operative care. According to a report published in The Lancet in 2021, the number of surgical procedures performed worldwide increased by 38.2% between 2008 and 2018, reaching 313 million each year.

Technological Advancements in Coagulation Analyzers:

Technological advances in blood coagulation analyzers, including increased accuracy and faster results, are driving market expansion. According to a 2022 National Institutes of Health (NIH) report, point-of-care coagulation testing equipment can already offer results in as little as 1-3 minutes, compared to typical laboratory procedures that take 30-60 minutes.

Key Challenges:

Technological Complexity:

Blood coagulation analyzers are complex instruments that require advanced technology and precision engineering. It might be difficult to keep up with rapid technological advances while maintaining accuracy and reliability. To remain competitive, manufacturers must consistently innovate and upgrade their systems, which requires major expenditure in R&D.

Data Management:

Modern coagulation analyzers generate a huge amount of data, which must be carefully recorded, stored, and processed. Effective data management systems are essential for ensuring that results are dependable and easily accessible. Integrating these technologies with other hospital information systems can be difficult.

Product Calibration and Maintenance:

Regular calibration and maintenance are required to ensure the accuracy and reliability of coagulation analyzers. This continual necessity can be difficult, particularly for healthcare facilities with limited resources, and may impact the operational efficiency and cost of employing these devices.

High Costs:

Blood coagulation analyzers can be expensive both to purchase and to maintain. This includes the cost of the equipment, consumables, and the necessity for periodic calibration and servicing. These high prices can be prohibitive for smaller clinics and laboratories, restricting access to advanced coagulation diagnostics.

Key Trends:

Point-of-Care Testing:

Point-of-care (POC) testing for blood coagulation is becoming more popular, as it provides quick, on-site results rather than sending samples to a central lab. This trend is motivated by the desire for faster diagnostic results and more patient convenience. POC devices are becoming smaller and more user-friendly, allowing for rapid decision-making in a variety of clinical settings, including emergency rooms and outpatient clinics.

Integration with Electronic Health Records (EHRs):

Blood coagulation analyzers are increasingly being linked to electronic health records (EHRs) to expedite data administration and improve patient care. This interface offers smooth data transfer, real-time access to patient information, and improved coordination among healthcare providers, hence increasing the overall efficiency of coagulation testing and management.

Miniaturization and Portability:

The development of small and portable blood coagulation analyzers is a major trend. These small instruments provide versatility and simplicity, enabling coagulation testing in a variety of contexts, including remote locations and home care settings. Portable analyzers address the growing demand for dispersed testing solutions.

Advanced Technology and Automation:

Blood coagulation analyzers are becoming more useful as a result of advances in automation and technology. Features such as automated sample handling, data processing, and result reporting are becoming increasingly common, enhancing accuracy, eliminating manual errors, and increasing test throughput.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Blood Coagulation Analyzer Market Regional Analysis

Here is a more detailed regional analysis of the global blood coagulation analyzer market:

North America:

North America continues to lead the blood coagulation analyzer market due to its excellent healthcare infrastructure, cutting-edge medical research, and the high prevalence of chronic disorders that necessitate regular coagulation monitoring. The region's well-established healthcare system promotes the widespread use of sophisticated diagnostic instruments, such as blood coagulation analyzers. According to the CDC, almost 900,000 Americans suffer from deep vein thrombosis or pulmonary embolism each year, with up to 100,000 deaths attributed to these illnesses. This high incidence highlights the urgent necessity for precise and rapid coagulation testing. The American Heart Association's 2024 update states that cardiovascular disorders affect roughly half of American adults, with many requiring continuing anticoagulant medication, increasing the requirement for dependable coagulation monitoring.

North America's enormous investments in medical technology and research strengthen its market supremacy. According to the National Institutes of Health, the region will account for more than 40% of worldwide healthcare R&D spending in 2023, with a large share going toward diagnostic technology such as blood coagulation analyzers. A growing emphasis on preventive healthcare and early detection is also a crucial driver, as indicated by a 2024 study that predicts an 8.5% annual growth rate in point-of-care coagulation testing across North America. This emphasis on rapid and accessible diagnostic solutions continues to drive market growth, establishing North America's dominant position in the blood coagulation analyzer sector.

Asia Pacific:

The Asia-Pacific area is rapidly emerging as the fastest-growing market for blood coagulation analyzers, owing to several revolutionary forces that are transforming the healthcare environment. Cardiovascular disorders account for 31% of all deaths in the region and about 6.2 million deaths per year, the extreme need for enhanced coagulation monitoring. This high prevalence contributes significantly to the rising demand for blood coagulation analyzers. The region's aging population is driving market growth. The United Nations Economic and Social Commission for Asia and the Pacific predicts that the number of older people in the region will quadruple by 2050, increasing the prevalence of age-related coagulation diseases and driving up the need for monitoring systems.

Rising healthcare expenditure in Asia-Pacific is also driving market expansion. This increased investment promotes the expansion of healthcare infrastructure and the availability of advanced diagnostic technology. Improved access to healthcare services for the region's growing middle class, combined with technology developments and improved awareness of blood problems, is fueling market growth. According to reports, point-of-care coagulation testing equipment use in India is growing at a 12% yearly rate, suggesting a regional trend toward rapid and accessible diagnostic options.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Blood Coagulation Analyzer Market: Segmentation Analysis

The Global Blood Coagulation Analyzer Market is Segmented on the basis of Technology, Test Type, Distribution Channel, And Geography.

Blood Coagulation Analyzer Market, By Technology

  • Optical Technology
  • Mechanical Technology
  • Electrochemical Technology

Based on Technology, the market is bifurcated into Optical Technology, Mechanical Technology, and Electrochemical Technology. Optical technology leads the blood coagulation analyzer market due to its great sensitivity, accuracy, and convenience. This method uses light to measure coagulation parameters, providing accurate and consistent results. On the other hand, electrochemical technology is emerging as the fastest-growing segment, given to its potential for downsizing and point-of-care applications. This method uses electrical signals to measure coagulation parameters, allowing for portable and convenient quick testing in a variety of scenarios.

Blood Coagulation Analyzer Market, By Test Type

  • APTT
  • D-Dimer
  • Fibrinogen
  • PT

Based on Test Type, the market is segmented into APTT, D-Dimer, Fibrinogen, and PT. The blood coagulation analyzer market is divided into two dominating segments: APTT and PT. APTT assesses the internal process of coagulation, whereas PT evaluates the extrinsic pathway. These tests are commonly used to assess patients with bleeding or clotting issues. D-dimer is a new segment that is quickly gaining popularity due to its significance in identifying deep vein thrombosis (DVT) and pulmonary embolism (PE). The rising prevalence of these disorders, combined with the development of more sensitive D-dimer testing, has accelerated its expansion.

Blood Coagulation Analyzer Market, By Distribution Channel

  • Clinical Laboratory
  • Point-of-Care (POC)
  • Hospitals

Based on Distribution Channel, the market is segmented into Clinical Laboratory, Point-of-Care (POC), and Hospitals. Hospitals dominate the blood coagulation analyzer market due to requiring extensive testing for a diverse spectrum of patients. However, point-of-care (POC) testing is emerging as the most rapidly rising area. POC devices provide fast outcomes at the bedside, allowing for timely decision-making in critical care settings. The growing demand for decentralized testing, combined with technological developments in POC analyzers, is propelling their implementation in a variety of healthcare settings.

Blood Coagulation Analyzer Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
  • On the basis of Geography, the Global Blood Coagulation Analyzer Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America continues to dominate the blood coagulation analyzer market due to its established healthcare infrastructure, advanced medical research, and high prevalence of chronic disorders. However, Asia-Pacific is emerging as the fastest-growing area, owing to reasons such as rising healthcare spending, increased awareness of blood coagulation disorders, and the expansion of healthcare infrastructure.

Key Players

  • The "Global Blood Coagulation Analyzer Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific, Inc., Maccura Biotechnology Co. Ltd., Diagnostica Stago SAS, and Helena Laboratories.
  • The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Blood Coagulation Analyzer Market Recent Developments
  • In July 2022, HORIBA Medical will release the latest Yumizen G800 and G1550 hemostasis analyzers, as well as a line of handy ready-to-use reagents for common blood coagulation assays. With the growth of its product line, HORIBA Medical now offers a full array of hemostasis systems and innovative reagents to laboratories of all sizes and needs.
  • In October 2021, Trivitron Healthcare announced the launch of a new line of Coagulation Analyzer products developed by Diagon Ltd. The newly announced product line includes the COAG Line, which includes automated, semi-automated, and POC systems developed by Diagon Hungary. These cutting-edge technologies are critical in decreasing bleeding risks during extensive procedures, as well as evaluating the efficacy of hemostatic treatments and anticoagulants.
  • In October 2021, Trivitron Healthcare, a medical device business, unveiled a new line of Coagulation Analyzer products in India, produced by Diagon Ltd.
  • In February 2021, Siemens Healthineers and Sysmex Corporation announced the renewal of their long-standing global supply, distributorship, sales, and service agreement for a broad portfolio of hemostasis devices, which included a multi-year extension.

TABLE OF CONTENTS

1. Introduction

  • Market Definition
  • Market Segmentation
  • Research Methodology

2. Executive Summary

  • Key Findings
  • Market Overview
  • Market Highlights

3. Market Overview

  • Market Size and Growth Potential
  • Market Trends
  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Porter's Five Forces Analysis

4. Blood Coagulation Analyzer Market, By Type of Analyzer

  • Clinical Laboratory Analyzers
  • Point-of-Care (POC) Analyzers

5. Blood Coagulation Analyzer Market, By Application

  • Routine Coagulation Tests
  • Special Coagulation Tests
  • Thrombophilia Testing
  • Other Applications

6. Blood Coagulation Analyzer Market, By End-User

  • Hospitals
  • Clinics and Physician Offices
  • Diagnostic Centers
  • Research Institutes

7. Regional Analysis

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Latin America
  • Brazil
  • Argentina
  • Chile
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

8. Market Dynamics

  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Impact of COVID-19 on the Market

9. Competitive Landscape

  • Key Players
  • Market Share Analysis

10. Company Profiles

  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Maccura Biotechnology Co. Ltd.
  • Diagnostica Stago SAS
  • Helena Laboratories

11. Market Outlook and Opportunities

  • Emerging Technologies
  • Future Market Trends
  • Investment Opportunities

12. Appendix

  • List of Abbreviations
  • Sources and References
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦